Results 1 to 10 of about 142,420 (373)

Cholangiocarcinoma [PDF]

open access: yesPathologica, 2021
Cholangiocarcinoma (CCA) is a highly lethal adenocarcinoma of the hepatobiliary system, which can be classified as intrahepatic, perihilar and distal.
P. Brindley   +8 more
semanticscholar   +13 more sources

Treatment of hilar cholangiocarcinoma (Klatskin tumors) with hepatic resection or transplantation [PDF]

open access: green, 1998
Background: Because of the rarity of hilar cholangiocarcinoma, its prognostic risk factors have not been sufficiently analyzed. This retrospective study was undertaken to evaluate various pathologic risk factors which influenced survival after curative ...
Dvorchik, I   +7 more
core   +3 more sources

Chemotherapeutic resistant cholangiocarcinoma displayed distinct intratumoral microbial composition and metabolic profiles [PDF]

open access: yesPeerJ, 2022
Background Cholangiocarcinoma (CCA) is a malignancy of the cholangiocytes. One of the major issues regarding treatment for CCA patients is the development of chemotherapeutic resistance.
Sirinya Sitthirak   +10 more
doaj   +2 more sources

Metabolomic analyses uncover an inhibitory effect of niclosamide on mitochondrial membrane potential in cholangiocarcinoma cells [PDF]

open access: yesPeerJ, 2023
Background Niclosamide is an oral anthelminthic drug that has been used for treating tapeworm infections. Its mechanism involves the disturbance of mitochondrial membrane potential that in turn inhibits oxidative phosphorylation leading to ATP depletion.
Thanaporn Kulthawatsiri   +9 more
doaj   +2 more sources

1H NMR fecal metabolic phenotyping of periductal fibrosis- and cholangiocarcinoma-specific metabotypes defining perturbation in gut microbial-host co-metabolism [PDF]

open access: yesPeerJ, 2023
Background The liver fluke Opisthorchis viverrini (OV), which subsequently inhabits the biliary system and results in periductal fibrosis (PDF), is one of the primarily causes of cholangiocarcinoma (CCA), a bile duct cancer with an exceptionally high ...
Rujikorn Treeriya   +12 more
doaj   +2 more sources

Futibatinib for FGFR2-Rearranged Intrahepatic Cholangiocarcinoma.

open access: yesNew England Journal of Medicine, 2023
BACKGROUND Alterations in fibroblast growth factor receptor 2 (FGFR2) have emerged as promising drug targets for intrahepatic cholangiocarcinoma, a rare cancer with a poor prognosis.
L. Goyal   +29 more
semanticscholar   +1 more source

Advances in the treatment of intrahepatic cholangiocarcinoma: An overview of the current and future therapeutic landscape for clinicians

open access: yesCa, 2022
Intrahepatic cholangiocarcinoma (ICC) is the second most common primary liver tumor and remains a fatal malignancy in the majority of patients. Approximately 20%–30% of patients are eligible for resection, which is considered the only potentially ...
D. Moris   +5 more
semanticscholar   +1 more source

Modification of the eighth AJCC/UICC staging system for perihilar cholangiocarcinoma: An alternative pathological staging system from cholangiocarcinoma-prevalent Northeast Thailand

open access: yesFrontiers in Medicine, 2022
AimThis study aims to improve the classification performance of the eighth American Joint Committee on Cancer (AJCC) staging system for perihilar cholangiocarcinoma (pCCA) by proposing the Khon Kaen University (KKU) staging system developed in ...
Chaiwat Aphivatanasiri   +51 more
doaj   +1 more source

Sulfasalazine modifies metabolic profiles and enhances cisplatin chemosensitivity on cholangiocarcinoma cells in in vitro and in vivo models

open access: yesCancer & Metabolism, 2021
Background Sulfasalazine (SSZ) is widely known as an xCT inhibitor suppressing CD44v9-expressed cancer stem-like cells (CSCs) being related to redox regulation. Cholangiocarcinoma (CCA) has a high recurrence rate and no effective chemotherapy.
Malinee Thanee   +12 more
doaj   +1 more source

Prognostic significance of tumor-infiltrating lymphocytes in predicting outcome of distal cholangiocarcinoma in Thailand

open access: yesFrontiers in Oncology, 2022
Patients with distal cholangiocarcinoma (dCCA) generally have poor outcomes because of late presentation and diagnosis. Therefore, prognostic factors for predicting outcomes are essential to improve therapeutic strategies and quality of life.
Piyapharom Intarawichian   +54 more
doaj   +1 more source

Home - About - Disclaimer - Privacy